マントル細胞リンパ腫市場-世界の産業規模、シェア、動向、機会、予測、診断別、治療別、エンドユーザー別、地域別、競合別、2020年～2030年

マントル細胞リンパ腫の世界市場は、2024年に25億3,000万米ドルと評価され、予測期間中にCAGR7.80％で成長し、2030年までには39億7,000万米ドルに達すると予測されています。

マントル細胞リンパ腫（MCL）は、非ホジキンリンパ腫のまれで侵攻性のサブタイプであり、リンパ系内でのBリンパ球の異常増殖を特徴とします。MCLはリンパ腫全体の症例に占める割合は少ないですが、進行が速く、治療法の選択肢が限られているため、臨床上重要な問題となっています。近年、特に患者の予後を改善することを目的とした標的療法や免疫療法の出現により、この分野で大きな進歩が見られています。化学療法や幹細胞移植のような従来の治療法では、長期的な成功は限られており、より特異的で毒性の少ない治療法への転換が促されています。MCL細胞の生存と増殖を維持する重要な経路を阻害するブルトン型チロシンキナーゼ（BTK）阻害剤やホスホイノシチド3キナーゼ（PI3K）阻害剤の導入は、画期的な進歩です。これらの技術革新は治療戦略を再構築し、MCL治療市場の可能性を拡大しています。

主要な市場促進要因

標的治療の進歩

主要な市場課題

疾患の不均一性

主要市場動向

投資と資金調達の増加

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のマントル細胞リンパ腫市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 診断別（臨床検査、画像検査、骨髄生検、その他）
  • 治療別（診断（画像検査、外科的検査、その他）、治療（化学療法、標的療法、免疫療法、幹細胞移植、その他））
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ
  • 診断別
  • 治療別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋のマントル細胞リンパ腫市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 診断別
  • 治療別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のマントル細胞リンパ腫市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のマントル細胞リンパ腫市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のマントル細胞リンパ腫市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのマントル細胞リンパ腫市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界のマントル細胞リンパ腫市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Kite Pharma, Inc.（Gilead Sciences, Inc.）
• F. Hoffman La Roche Ltd
• Abbvie, Inc.
• Celgene Corporation
• Eli Lilly and Company
• Amgen, Inc.
• Takeda Pharmaceutical Co. Ltd
• AstraZeneca Plc
• Johnson and Johnson Services Inc.
• BeiGene GmBH

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Mantle Cell Lymphoma Market was valued at USD 2.53 billion in 2024 and is projected to reach USD 3.97 billion by 2030, growing at a CAGR of 7.80% during the forecast period. Mantle cell lymphoma (MCL), a rare and aggressive subtype of non-Hodgkin lymphoma, is characterized by the abnormal proliferation of B lymphocytes within the lymphatic system. Although MCL accounts for a small proportion of overall lymphoma cases, its rapid progression and limited curative treatment options make it a significant clinical concern. Recent years have seen substantial advancements in the field, particularly with the emergence of targeted therapies and immunotherapies aimed at improving patient outcomes. Traditional methods, such as chemotherapy and stem cell transplantation, have shown restricted long-term success, prompting a shift towards more specific and less toxic treatments. Notable breakthroughs include the introduction of Bruton's tyrosine kinase (BTK) inhibitors and phosphoinositide 3-kinase (PI3K) inhibitors, which interfere with critical pathways that sustain MCL cell survival and proliferation. These innovations are reshaping therapeutic strategies and expanding the market potential for MCL treatments.

Key Market Drivers

Advancements in Targeted Therapies

Technological progress in targeted therapies is a major catalyst for growth in the global mantle cell lymphoma market. MCL, known for its resistance to conventional treatments, has seen a significant transformation with the development of targeted approaches like BTK inhibitors, including ibrutinib, which specifically disrupt the BTK signaling protein that promotes tumor cell survival. These therapies have shown marked improvements in progression-free survival and patient quality of life, thereby attracting growing attention from healthcare providers and industry stakeholders. Additionally, PI3K inhibitors offer an alternative for patients not responding to BTK therapies, further diversifying the treatment landscape. The advancement of combination regimens, integrating multiple targeted agents, also holds promise for enhancing therapeutic efficacy and minimizing resistance. These innovations, supported by biomarker research and genetic profiling, are enabling more personalized treatment protocols and reinforcing the expansion of the MCL market.

Key Market Challenges

Heterogeneity of Disease

The complexity and variability of mantle cell lymphoma present a critical challenge to its clinical management and market growth. MCL encompasses a wide spectrum of disease behaviors-from indolent to highly aggressive subtypes-making it difficult to standardize treatment approaches. The diversity in disease progression among patients necessitates personalized therapy plans, which increases the difficulty of creating one-size-fits-all treatment models. Furthermore, the genetic heterogeneity of MCL tumors complicates drug development, as different mutations and molecular subtypes respond variably to treatment. This also hampers clinical trial design, as many studies focus on specific patient segments, limiting the generalizability of results across the broader MCL population.

Key Market Trends

Rising Investments and Funding

Increased investment and funding are playing a pivotal role in propelling the growth of the mantle cell lymphoma market. With the emergence of promising therapies, the MCL segment has attracted substantial attention from pharmaceutical companies, venture capitalists, and institutional investors. This surge in financial backing is accelerating research and development efforts, facilitating the introduction of innovative therapies and expanding access to advanced treatment options. Alongside private investment, public grants and nonprofit initiatives are also bolstering academic research, patient support services, and advocacy efforts. These combined financial inputs are enhancing manufacturing capabilities, supporting awareness campaigns, and strengthening the overall ecosystem for MCL treatment and management.

Key Market Players

• Kite Pharma, Inc. (Gilead Sciences, Inc.)
• F. Hoffman La Roche Ltd
• Abbvie, Inc.
• Celgene Corporation
• Eli Lilly and Company
• Amgen, Inc.
• Takeda Pharmaceutical Co. Ltd
• AstraZeneca Plc
• Johnson and Johnson Services Inc.
• BeiGene GmBH

Report Scope:

In this report, the Global Mantle Cell Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mantle Cell Lymphoma Market, By Diagnosis:

• Laboratory Exams
• Imaging Tests
• Bone Marrow Biopsy
• Others

Mantle Cell Lymphoma Market, By Treatment:

• Diagnosis
• Therapy

Mantle Cell Lymphoma Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Mantle Cell Lymphoma Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mantle Cell Lymphoma Market.

Available Customizations:

Global Mantle Cell Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Mantle Cell Lymphoma Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Diagnosis (Laboratory exams, Imaging Tests, Bone marrow Biopsy, Others)
  • 4.2.2. By Treatment (Diagnosis {Imaging Tests, Surgical Examination, Others}, Therapy{Chemotherapy, Targeted therapy, Immunotherapy, Stem Cell Transplantation, Others)
  • 4.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Diagnosis
  • 4.3.2. By Treatment
  • 4.3.3. By End User
  • 4.3.4. By Region

5. Asia Pacific Mantle Cell Lymphoma Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis
  • 5.2.2. By Treatment
  • 5.2.3. By End User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Mantle Cell Lymphoma Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Diagnosis
      • 5.3.1.2.2. By Treatment
      • 5.3.1.2.3. By End User
  • 5.3.2. India Mantle Cell Lymphoma Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Diagnosis
      • 5.3.2.2.2. By Treatment
      • 5.3.2.2.3. By End User
  • 5.3.3. Australia Mantle Cell Lymphoma Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Diagnosis
      • 5.3.3.2.2. By Treatment
      • 5.3.3.2.3. By End User
  • 5.3.4. Japan Mantle Cell Lymphoma Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Diagnosis
      • 5.3.4.2.2. By Treatment
      • 5.3.4.2.3. By End User
  • 5.3.5. South Korea Mantle Cell Lymphoma Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Diagnosis
      • 5.3.5.2.2. By Treatment
      • 5.3.5.2.3. By End User

6. Europe Mantle Cell Lymphoma Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis
  • 6.2.2. By Treatment
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Mantle Cell Lymphoma Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End User
  • 6.3.2. Germany Mantle Cell Lymphoma Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End User
  • 6.3.3. Spain Mantle Cell Lymphoma Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End User
  • 6.3.4. Italy Mantle Cell Lymphoma Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Diagnosis
      • 6.3.4.2.2. By Treatment
      • 6.3.4.2.3. By End User
  • 6.3.5. United Kingdom Mantle Cell Lymphoma Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Diagnosis
      • 6.3.5.2.2. By Treatment
      • 6.3.5.2.3. By End User

7. North America Mantle Cell Lymphoma Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis
  • 7.2.2. By Treatment
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Mantle Cell Lymphoma Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End User
  • 7.3.2. Mexico Mantle Cell Lymphoma Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End User
  • 7.3.3. Canada Mantle Cell Lymphoma Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End User

8. South America Mantle Cell Lymphoma Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis
  • 8.2.2. By Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Mantle Cell Lymphoma Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End User
  • 8.3.2. Argentina Mantle Cell Lymphoma Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End User
  • 8.3.3. Colombia Mantle Cell Lymphoma Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End User

9. Middle East and Africa Mantle Cell Lymphoma Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis
  • 9.2.2. By Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Mantle Cell Lymphoma Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End User
  • 9.3.2. Saudi Arabia Mantle Cell Lymphoma Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End User
  • 9.3.3. UAE Mantle Cell Lymphoma Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Mantle Cell Lymphoma Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Kite Pharma, Inc. (Gilead Sciences, Inc.)
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. F. Hoffman La Roche Ltd
• 14.3. Abbvie, Inc.
• 14.4. Celgene Corporation
• 14.5. Eli Lilly and Company
• 14.6. Amgen, Inc.
• 14.7. Takeda Pharmaceutical Co. Ltd
• 14.8. AstraZeneca Plc
• 14.9. Johnson and Johnson Services Inc.
• 14.10. BeiGene GmBH

15. Strategic Recommendations

16. About Us & Disclaimer